ArticleACS biomaterials science & engineering2025
Polydopamine-Coated Poly(l-lactide) Nanofibers with Controlled Release of IL-10 for Effective Management of Peripheral and Central Neuropathic Pain in Rats.
Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Managing neuropathic pain is challenging due to the complex pathogenetic mechanisms and limited available drugs and therapeutic options. Innovative nanofiber systems offer a novel method to effectively administer therapeutic cytokines, drugs, or small molecule compounds to achieve better relief of neuropathic pain. Here, we report a novel nanofiber with controlled release of IL-10 for implantation into ligated nerve roots and hemisection-injured spinal cords to exert anti-inflammatory effects and attenuate neuropathic pain. An electrospun poly(l-lactide) (PLLA) nanofiber was modified by a polydopamine (PDA) coating, and this nanofiber demonstrated sustained release of IL-10 in vitro. We showed that L5 spinal nerve ligation and T13 spinal cord hemisection induced peripheral and below-level central neuropathic pain in rats, along with the development of neuroinflammation. Spinal IL-10 was also markedly changed after spinal nerve ligation (SNL) or spinal cord injury (SCI), especially in the spinal dorsal horn. Rats were treated postsurgically with IL-10 that was loaded on PDA@PLLA nanofibers as an implantable cytokine delivery system. IL-10 levels were significantly upregulated after the implantation of PDA@PLLA nanofibers in SNL and SCI rats. We further demonstrated that the implantation could inhibit glial activation and neuronal excitability in vivo, along with suppressing the expression levels of pro-inflammatory cytokines. Most importantly, IL-10-loaded PDA@PLLA nanofiber treatment attenuated the development and maintenance of peripheral and central neuropathic pain. Together, the combination of IL-10 and PDA@PLLA nanofibers provides a novel implantable delivery system for treating neuroinflammatory conditions and may emerge as a promising agent to prevent chronic neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.